The Bordeaux-based optronic company recovers ground on Monday, in an almost stable SBF 120, posting one of the index's best daily performances. The rebound comes after several weeks of pressure on the security, which had lagged behind its early summer levels.
A Rebound Supported by Nearby Resistance as Moving Averages Cap the Stock
Exosens gains 3.26% to €57.00 during the session, while the SBF 120 advances by only 0.09%. The stock remains however below its three moving averages: the 200-day MA at €58.24 stands 2.13% above the price, the 50-day MA at €59.67 shows a gap of 4.47%, and the 20-day MA at €61.52 widens the gap further (-7.35%). This configuration reflects medium-term dynamics still oriented downward, even though today's rebound partially offsets the monthly decline of 10.24%.
The price nevertheless evolves just above the support level at €56.45, a level tested closely during recent sessions. The RSI at 39, approaching oversold territory without plunging into it, signals exhaustion of selling pressure without confirmation of a reversal.
Exosens Anchored in Optronic Defense, with Confirmed U.S. Commercial Momentum
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Fundamentally, Exosens recorded a notable commercial milestone in the United States at end of August: the U.S. Army's first order on the BiNOD binocular night vision program, obtained through its Photonis Defense subsidiary as part of an IDIQ master contract announced in March 2026. Prior to this order, the company published solid first-half results on July 28, 2026, with growth of 15.3% and record adjusted EBITDA margin at 33.0%. Over one year, the stock still shows a gain of 55.53%, reflecting a trajectory driven by the expansion of the optronic defense market, a sector cited among opportunities when first-quarter 2026 results were published (April 27, 2026). The analyst consensus on the stock remains to be monitored to assess whether the decline of recent weeks has altered views on the value.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
